Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

Ashutosh Wechalekar, MD FRCPath, Darren Foard, Carol Whelan, MD FRCP, Mariana Fontana, Thirusha Lane, RN MSc, Candida Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MD FRCP, Julian D Gillmore, MD PhD FRCP, Philip N Hawkins, MD PhD FMedSci

Blood (2016) 128 (22): 4511.

https://doi.org/10.1182/blood.V128.22.4511.4511

Published: 2016

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MDFRCP, Helen Lachmann, MDFRCP, Marianna Fontana, MD, Shameem Mahmood, FRCPath, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 732.

https://doi.org/10.1182/blood.V126.23.732.732

Published: 2015

Journal Articles

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MD, Sajitha Sachchithanantham, MRCP, FRCPath, Marianna Fontana, MD, Shameem Mahmood, MRCP. FRCPath, Darren Foard, RN, Thirusha Lane, RN, Helen J Lachmann, MD FRCP, Julian D Gillmore, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci

Blood (2014) 124 (21): 3485.

https://doi.org/10.1182/blood.V124.21.3485.3485

Published: 2014

Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 1981.

https://doi.org/10.1182/blood.V122.21.1981.1981

Published: 2013

Journal Articles

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Shameem Mahmood, MRCP. FRCPath, Sajitha Sachchithanantham, MRCP. FRCPath, Frank Bridoux, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontanna, MD, Carol Whelan, MD, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3143.

https://doi.org/10.1182/blood.V122.21.3143.3143

Published: 2013

Journal Articles

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

Brian A Walker, PhD, Dorota Rowczienio, MSc, Eileen M Boyle, MD, Christopher P Wardell, PhD, Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Julian D Gillmore, MD, Shameem Mahmood, MRCP. FRCPath, Helen J Lachmann, MD, FRCP, Philip N Hawkins, Faith E Davies, MD, Gareth J Morgan, MD PhD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 3098.

https://doi.org/10.1182/blood.V122.21.3098.3098

Published: 2013

Journal Articles

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Dorota Rowczenio, Shameem Mahmood, MRCP, FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3120.

https://doi.org/10.1182/blood.V122.21.3120.3120

Published: 2013

Journal Articles

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Christopher P Venner, MD, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Shameem Mahmood, MBBCh. FRCPath, Simon DJ Gibbs, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD

Blood (2012) 120 (21): 2966.

https://doi.org/10.1182/blood.V120.21.2966.2966

Published: 2012

Journal Articles

Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis

Murielle Roussel, MD, Giovanni Palladini, Simon DJ Gibbs, Christopher P. Venner, MD, Jean-Paul Fermand, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Giampaolo Merlini, Arnaud Jaccard, Ashutosh Wechalekar, MD

Blood (2012) 120 (21): 4074.

https://doi.org/10.1182/blood.V120.21.4074.4074

Published: 2012

Journal Articles

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

Shameem Mahmood, MBBCh. FRCPath, Christopher P. Venner, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2012) 120 (21): 2978.

https://doi.org/10.1182/blood.V120.21.2978.2978

Published: 2012

Journal Articles

ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis

Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Ashutosh Wechalekar, MD, Simon Gibbs, MD, Jennifer Pinney, MD, Christopher P Venner, MD, Sanjay Banypersad, MD, Helen Lachmann, MD, Philip N Hawkins, MD, Julian D Gillmore, MD

Blood (2011) 118 (21): 992.

https://doi.org/10.1182/blood.V118.21.992.992

Published: 2011

Journal Articles

Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,

Christopher P. Venner, MD, Julian D Gillmore, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Simon DJ Gibbs, Jennifer Pinney, MD, Carol Whelan, Helen Lachmann, MD, Philip N Hawkins, Ashutosh Wechalekar, MD

Blood (2011) 118 (21): 3975.

https://doi.org/10.1182/blood.V118.21.3975.3975

Published: 2011

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,

Blood (2011) 118 (21): 3978.

https://doi.org/10.1182/blood.V118.21.3978.3978

Published: 2011

Journal Articles

European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease

Ashutosh Wechalekar, MD, Stefan O Schonland, MD, Efstathios Kastritis, Philip N Hawkins, Meletios A. Dimopoulos, Paola Russo, MD, Thirusha Lane, RN, Andrea Foli, MD, Darren Foard, RN, Paolo Milani, MD, Lisa Rannigan, RN, Ute Hegenbart, Julian D Gillmore, Giampaolo Merlini, Giovanni Palladini

Blood (2011) 118 (21): 995.

https://doi.org/10.1182/blood.V118.21.995.995

Published: 2011

Journal Articles

Validation of the Criteria of Response to Treatment In AL Amyloidosis.

Giovanni Palladini, MD, PhD, Angela Dispenzieri, MD, Morie Abraham A Gertz, MD, Ashutosh Wechalekar, MD, Philip N Hawkins, MD, Stefan O Schonland, MD, Ute Hegenbart, MD, Raymond L. Comenzo, MD, Efstathios Kastritis, MD, Meletios A. Dimopoulos, MD, Arnaud Jaccard, MD, Catherine Klersy, MD, Giampaolo Merlini, MD

Blood (2010) 116 (21): 1364.

https://doi.org/10.1182/blood.V116.21.1364.1364

Published: 2010

Journal Articles

Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases

Helen J Lachmann, MD, FRCP, Stephen Harding, PhD, Ashutosh Wechalekar, MD, FRCPath, Julian D Gillmore, E. Nicole Amft, MD, PhD, FRCP, Philip N Hawkins

Blood (2010) 116 (21): 3958.

https://doi.org/10.1182/blood.V116.21.3958.3958

Published: 2010

Journal Articles

Critical Importance of Conventional Cytogenetics in Detecting Prognostically Significant Chromosome 13 Deletions in Myeloma.

Laura Chiecchio, MBS, Rebecca K.M. Protheroe, BSc, Tim Parker, BSc, Christina Rudduck, PhD, Kan Luk Cheung, BSc, Gianpaolo Dagrada, MBS, Ashutosh Wechalekar, MD, Mathew Nightingale, BSc, Christine J. Harrison, PhD, Nicholas C.P. Cross, PhD, Fiona M. Ross, DPhil

Blood (2005) 106 (11): 1544.

https://doi.org/10.1182/blood.V106.11.1544.1544

Published: 2005

NARROW

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis

Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,

Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,

European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease

Validation of the Criteria of Response to Treatment In AL Amyloidosis.

Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases

Critical Importance of Conventional Cytogenetics in Detecting Prognostically Significant Chromosome 13 Deletions in Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only